Since 2022, DMS Group, the French leader in conventional radiology, has streamlined its portfolio by refocusing on medical imaging and launched an ambitious strategy out to 2027 (#Imaging2027). The goal is to achieve € 70m in revenue (vs. € 46m in 2024) and generate an EBITDA margin of 14% (vs. 6% in 2024). The hybrid model introduced by the new management (OEM and own brand), supported by a differentiated offering (Platinum, Stratos, Onyx, !M1, ADAM), opens up a cycle of profitable growth. We a...
Depuis 2022, DMS Group, leader français de la radiologie conventionnelle, a rationalisé son portefeuille en recentrant son activité sur l’imagerie médicale et lancé une stratégie ambitieuse à horizon 2027 (#Imaging2027). L’objectif est d’atteindre 70 M€ de revenus (vs 46 M€ en 2024) et de générer une marge d’EBITDA de 14% (vs 6% en 2024). Le modèle hybride insufflé par le nouveau management (OEM et marque propre), soutenu par une offre différenciante (Platinum, Stratos, Onyx, !M1, ADAM), ouvre u...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.